NRAS and melanoma: Combining trametinib with the clinically relevant BETi OTX‐015 more potently induced cell death compared to single agents (Appendix Fig S3), further supporting the notion that the combination of BET and MEK inhibitors elicit cytotoxic effects in NRAS‐mutant melanoma.